<DOC>
	<DOC>NCT01952392</DOC>
	<brief_summary>Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome</brief_summary>
	<brief_title>Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome</brief_title>
	<detailed_description>AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary. No Exclusion Criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Effectiveness study</keyword>
	<keyword>Acute coronary Syndrome</keyword>
	<keyword>Real-life</keyword>
	<keyword>France</keyword>
</DOC>